CCR Milestones: Annual Highlights 2019

An innovative strategy for mining cancer genomes finds enzymes with tumor-suppressing roles.

Preventing interaction between two immune proteins could improve treatment of HIV infection with implications for cancer immunotherapy.

Infection-fighting white blood cells could be a key element in developing an effective vaccine treatment against HIV/AIDS.

Bacteria in the gut have a profound impact on our health and rein in tumor-fighting immune cells in the liver.

After decades, a research endeavor produces an FDA-approved, toxin-based drug to treat relapsed or refractory hairy cell leukemia.

In a landmark study, a patient’s advanced breast cancer regressed completely after treatment with immune cells that recognized products of mutations specific to her cancer.

A compound that reduces the prevalence of an enigmatic cellular structure linked to metastasis blocks the spread of cancer in animals.

Deepened understanding of what drives different blood cancers is paving the way to more precise treatments.

Inhibiting an enzyme in the growth-promoting Ras pathway could stop the childhood cancer rhabdomyosarcoma.

New computational tool analyzes gene expression to predict which melanoma patients will benefit from immunotherapy.

A protein called RepID is key to regulating DNA replication and preventing cancer when the process goes awry.

A blood-clotting protein on the surface of tumor cells enables metastasis, the leading cause of death in cancer patients.

Fluorescent probes help biologists illuminate the inner workings of cancer cells. A new class of far-red fluorescent probes peers deeper into live tissues.

New faculty join CCR each year to contribute to our work of making breakthrough scientific discoveries to find cures and treatments for cancer.